Cargando…
Pembrolizumab monotherapy in advanced NSCLC patients with low PD-L1 expression: is there real evidence?
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
AME Publishing Company
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8799010/ https://www.ncbi.nlm.nih.gov/pubmed/35117144 http://dx.doi.org/10.21037/tcr.2019.06.28 |
| _version_ | 1784641962598465536 |
|---|---|
| author | Fiorelli, Alfonso Vitiello, Fabiana Morgillo, Floriana Santagata, Mario Spuntarelli, Chiara Di Domenico, Marina Santini, Mario Bianco, Andrea |
| author_facet | Fiorelli, Alfonso Vitiello, Fabiana Morgillo, Floriana Santagata, Mario Spuntarelli, Chiara Di Domenico, Marina Santini, Mario Bianco, Andrea |
| author_sort | Fiorelli, Alfonso |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8799010 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2019 |
| publisher | AME Publishing Company |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-87990102022-02-02 Pembrolizumab monotherapy in advanced NSCLC patients with low PD-L1 expression: is there real evidence? Fiorelli, Alfonso Vitiello, Fabiana Morgillo, Floriana Santagata, Mario Spuntarelli, Chiara Di Domenico, Marina Santini, Mario Bianco, Andrea Transl Cancer Res Editorial Commentary AME Publishing Company 2019-12 /pmc/articles/PMC8799010/ /pubmed/35117144 http://dx.doi.org/10.21037/tcr.2019.06.28 Text en 2019 Translational Cancer Research. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/. |
| spellingShingle | Editorial Commentary Fiorelli, Alfonso Vitiello, Fabiana Morgillo, Floriana Santagata, Mario Spuntarelli, Chiara Di Domenico, Marina Santini, Mario Bianco, Andrea Pembrolizumab monotherapy in advanced NSCLC patients with low PD-L1 expression: is there real evidence? |
| title | Pembrolizumab monotherapy in advanced NSCLC patients with low PD-L1 expression: is there real evidence? |
| title_full | Pembrolizumab monotherapy in advanced NSCLC patients with low PD-L1 expression: is there real evidence? |
| title_fullStr | Pembrolizumab monotherapy in advanced NSCLC patients with low PD-L1 expression: is there real evidence? |
| title_full_unstemmed | Pembrolizumab monotherapy in advanced NSCLC patients with low PD-L1 expression: is there real evidence? |
| title_short | Pembrolizumab monotherapy in advanced NSCLC patients with low PD-L1 expression: is there real evidence? |
| title_sort | pembrolizumab monotherapy in advanced nsclc patients with low pd-l1 expression: is there real evidence? |
| topic | Editorial Commentary |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8799010/ https://www.ncbi.nlm.nih.gov/pubmed/35117144 http://dx.doi.org/10.21037/tcr.2019.06.28 |
| work_keys_str_mv | AT fiorellialfonso pembrolizumabmonotherapyinadvancednsclcpatientswithlowpdl1expressionisthererealevidence AT vitiellofabiana pembrolizumabmonotherapyinadvancednsclcpatientswithlowpdl1expressionisthererealevidence AT morgillofloriana pembrolizumabmonotherapyinadvancednsclcpatientswithlowpdl1expressionisthererealevidence AT santagatamario pembrolizumabmonotherapyinadvancednsclcpatientswithlowpdl1expressionisthererealevidence AT spuntarellichiara pembrolizumabmonotherapyinadvancednsclcpatientswithlowpdl1expressionisthererealevidence AT didomenicomarina pembrolizumabmonotherapyinadvancednsclcpatientswithlowpdl1expressionisthererealevidence AT santinimario pembrolizumabmonotherapyinadvancednsclcpatientswithlowpdl1expressionisthererealevidence AT biancoandrea pembrolizumabmonotherapyinadvancednsclcpatientswithlowpdl1expressionisthererealevidence |